$1.02 Billion is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 133 reported holdings in Q2 2015. The portfolio turnover from Q1 2015 to Q2 2015 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGN | New | ALLERGAN PLC | $53,743,000 | – | 177,100 | +100.0% | 5.26% | – |
| New | PERRIGO CO PLCcall | $18,483,000 | – | 1,000 | +100.0% | 1.81% | – | |
| New | BIOMARIN PHARMACEUTICAL INCcall | $13,678,000 | – | 1,000 | +100.0% | 1.34% | – | |
| CXRX | New | CONCORDIA HEALTHCARE CORP | $9,025,000 | – | 100,000 | +100.0% | 0.88% | – |
| BCOMF | New | B COMMUNICATIONS LTD | $6,448,000 | – | 5,977,000 | +100.0% | 0.63% | – |
| CYNA | New | CYNAPSUS THERAPEUTICS INC | $5,324,000 | – | 316,448 | +100.0% | 0.52% | – |
| TSRO | New | TESARO INC | $5,144,000 | – | 87,500 | +100.0% | 0.50% | – |
| CATB | New | CATABASIS PHARMACEUTICALS IN | $5,060,000 | – | 446,036 | +100.0% | 0.50% | – |
| ACOR | New | ACORDA THERAPEUTICS INC | $5,000,000 | – | 150,000 | +100.0% | 0.49% | – |
| RARE | New | ULTRAGENYX PHARMACEUTICAL IN | $4,884,000 | – | 47,700 | +100.0% | 0.48% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $4,565,000 | – | 150,000 | +100.0% | 0.45% | – |
| 3106PS | New | DELPHI AUTOMOTIVE PLC | $4,516,000 | – | 53,070 | +100.0% | 0.44% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $4,435,000 | – | 37,000 | +100.0% | 0.43% | – |
| KMPH | New | KEMPHARM INC | $4,363,000 | – | 237,500 | +100.0% | 0.43% | – |
| BITI | New | BIOTIE THERAPIES OYJsponsored adr | $3,930,000 | – | 196,800 | +100.0% | 0.38% | – |
| NVLS | New | NIVALIS THERAPEUTICS INC | $3,863,000 | – | 255,000 | +100.0% | 0.38% | – |
| LIFE | New | ATYR PHARMA INC | $3,696,000 | – | 209,027 | +100.0% | 0.36% | – |
| KRE | New | SPDR SERIES TRUSTs&p regl bkg | $3,536,000 | – | 80,080 | +100.0% | 0.35% | – |
| DVAX | New | DYNAVAX TECHNOLOGIES CORP | $3,514,000 | – | 150,000 | +100.0% | 0.34% | – |
| ARWR | New | ARROWHEAD RESH CORP | $3,396,000 | – | 475,000 | +100.0% | 0.33% | – |
| HALO | New | HALOZYME THERAPEUTICS INC | $3,387,000 | – | 150,000 | +100.0% | 0.33% | – |
| OCUL | New | OCULAR THERAPEUTIX INC | $3,365,000 | – | 160,000 | +100.0% | 0.33% | – |
| PIRS | New | PIERIS PHARMACEUTICALS INC | $3,300,000 | – | 1,200,000 | +100.0% | 0.32% | – |
| RPTP | New | RAPTOR PHARMACEUTICAL CORP | $3,261,000 | – | 206,500 | +100.0% | 0.32% | – |
| XLRN | New | ACCELERON PHARMA INC | $3,164,000 | – | 100,000 | +100.0% | 0.31% | – |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $3,105,000 | – | 125,000 | +100.0% | 0.30% | – |
| MLNX | New | MELLANOX TECHNOLOGIES LTD | $3,054,000 | – | 62,850 | +100.0% | 0.30% | – |
| CBYL | New | CARBYLAN THERAPEUTICS INC | $2,860,000 | – | 400,000 | +100.0% | 0.28% | – |
| WIX | New | WIX COM LTD | $2,842,000 | – | 120,305 | +100.0% | 0.28% | – |
| CYTK | New | CYTOKINETICS INC | $2,838,000 | – | 422,250 | +100.0% | 0.28% | – |
| CLCD | New | COLUCID PHARMACEUTICALS INC | $2,824,000 | – | 317,250 | +100.0% | 0.28% | – |
| ISIS | New | ISIS PHARMACEUTICALS INC | $2,762,000 | – | 48,000 | +100.0% | 0.27% | – |
| SCYX | New | SCYNEXIS INC | $2,751,000 | – | 313,000 | +100.0% | 0.27% | – |
| TBRA | New | TOBIRA THERAPEUTICS INC | $2,374,000 | – | 137,622 | +100.0% | 0.23% | – |
| CHTR | New | CHARTER COMMUNICATIONS INC Dcl a new | $1,724,000 | – | 10,065 | +100.0% | 0.17% | – |
| New | APTOSE BIOSCIENCES INC | $1,415,000 | – | 221,096 | +100.0% | 0.14% | – | |
| NICE | New | NICE SYS LTDsponsored adr | $1,161,000 | – | 18,250 | +100.0% | 0.11% | – |
| CARA | New | CARA THERAPEUTICS INC | $567,000 | – | 46,700 | +100.0% | 0.06% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-08-06
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.